Albert Bourla, CEO of Pfizer, joins 'Money Movers' to discuss drug pricing, the impact on artificial intelligence on ...

Big pharma is grappling with new drug pricing deals and roughly $300 billion in potential lost revenue from patent ...

U.S. pharmaceutical companies are stepping up their campaign for higher drug prices in Europe, in some cases threatening to ...

US pharma giants seek to dodge Trump’s campaign to lower drug costs . American pharmaceutical corporations are reportedly ...

Trump's approval rating on the economy currently stands at a lackluster 36%, below his overall 41% rating even as he portrays ...

Pharmaceutical companies seek to make up lost revenue after striking deals with Donald Trump to lower costs in US ...

David Ricks, CEO of the Indiana drugmaker, has cut deals with the president to slash prices and build American. Trump has ...

Business leaders are urged to defend free markets against government control. Many top executives are hesitant to openly ...

A day earlier, Albert Bourla, CEO of Pfizer, said he was annoyed by Health Secretary Robert F Kennedy Jr's move to roll back ...

Despite an unusual lack of major announcements, energy is high. And a few key themes dominate discussions.

According to reporting from Bloomberg at the J.P. Morgan Healthcare Conference that ended today in San Francisco, ...

The vast majority of people on transplant waiting lists need a kidney, AP reported. An analysis of federal data found that 116 fewer kidney transplants were performed in 2025 than the year before. The ...